Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Institute of Biotechnology, Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Diabetologia. 2024 Sep;67(9):1930-1942. doi: 10.1007/s00125-024-06192-7. Epub 2024 Jun 4.
AIMS/HYPOTHESIS: The gut microbiome is implicated in the disease process leading to clinical type 1 diabetes, but less is known about potential changes in the gut microbiome after the diagnosis of type 1 diabetes and implications in glucose homeostasis. We aimed to analyse potential associations between the gut microbiome composition and clinical and laboratory data during a 2 year follow-up of people with newly diagnosed type 1 diabetes, recruited to the Innovative approaches to understanding and arresting type 1 diabetes (INNODIA) study. In addition, we analysed the microbiome composition in initially unaffected family members, who progressed to clinical type 1 diabetes during or after their follow-up for 4 years.
We characterised the gut microbiome composition of 98 individuals with newly diagnosed type 1 diabetes (ND cohort) and 194 autoantibody-positive unaffected family members (UFM cohort), representing a subgroup of the INNODIA Natural History Study, using metagenomic sequencing. Participants from the ND cohort attended study visits within 6 weeks from the diagnosis and 3, 6, 12 and 24 months later for stool sample collection and laboratory tests (HbA, C-peptide, diabetes-associated autoantibodies). Participants from the UFM cohort were assessed at baseline and 6, 12, 18, 24 and 36 months later.
We observed a longitudinal increase in 21 bacterial species in the ND cohort but not in the UFM cohort. The relative abundance of Faecalibacterium prausnitzii was inversely associated with the HbA levels at diagnosis (p=0.0019). The rate of the subsequent disease progression in the ND cohort, as assessed by change in HbA, C-peptide levels and insulin dose, was associated with the abundance of several bacterial species. Individuals with rapid decrease in C-peptide levels in the ND cohort had the lowest gut microbiome diversity. Nineteen individuals who were diagnosed with type 1 diabetes in the UFM cohort had increased abundance of Sutterella sp. KLE1602 compared with the undiagnosed UFM individuals (p=1.2 × 10).
CONCLUSIONS/INTERPRETATION: Our data revealed associations between the gut microbiome composition and the disease progression in individuals with recent-onset type 1 diabetes. Future mechanistic studies as well as animal studies and human trials are needed to further validate the significance and causality of these associations.
目的/假设:肠道微生物群与导致临床 1 型糖尿病的疾病过程有关,但对 1 型糖尿病诊断后肠道微生物群的潜在变化及其对葡萄糖稳态的影响知之甚少。我们旨在分析新诊断为 1 型糖尿病的患者在创新方法理解和阻止 1 型糖尿病(INNODIA)研究中 2 年随访期间肠道微生物组组成与临床和实验室数据之间的潜在关联。此外,我们分析了在最初未受影响的家族成员中的微生物组组成,这些成员在他们的随访期间或之后的 4 年内进展为临床 1 型糖尿病。
我们使用宏基因组测序对 98 名新诊断为 1 型糖尿病的患者(ND 队列)和 194 名自身抗体阳性的未受影响的家族成员(UFM 队列)的肠道微生物组组成进行了特征描述,这是 INNODIA 自然史研究的一个亚组。ND 队列的参与者在诊断后 6 周内以及 3、6、12 和 24 个月后进行研究访问,以收集粪便样本和进行实验室测试(HbA、C 肽、与糖尿病相关的自身抗体)。UFM 队列的参与者在基线时以及 6、12、18、24 和 36 个月后进行评估。
我们观察到 ND 队列中 21 种细菌的纵向增加,但在 UFM 队列中没有观察到。普氏粪杆菌的相对丰度与诊断时的 HbA 水平呈负相关(p=0.0019)。ND 队列中随后的疾病进展速度,如 HbA、C 肽水平和胰岛素剂量的变化所评估的,与几种细菌物种的丰度有关。ND 队列中 C 肽水平迅速下降的个体肠道微生物组多样性最低。UFM 队列中 19 名被诊断为 1 型糖尿病的个体与未被诊断的 UFM 个体相比,苏特罗尔氏菌 KLE1602 的丰度增加(p=1.2×10)。
结论/解释:我们的数据揭示了肠道微生物组组成与近期发生 1 型糖尿病患者疾病进展之间的关联。需要进一步的机制研究、动物研究和人体试验来进一步验证这些关联的意义和因果关系。